Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
Zhang, Xiangmei, Zhang, Shuo, Li, Zhong, Niu, Fengling, Cai, Haifeng, Li, Xianqiao, Han, Meng, Huang, Ruixue, Liu, Yunjiang
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02
Zhang, Lina, Geng, Cuizhi, Liu, Yueping, Han, Jianjun, Han, Meng, Huang, Ruixue, Li, Xianqiao, Luo, Ruizhen, Li, Yuntao, Ma, Jie, Qi, Huaihua, Wang, Zunyi, Wang, Xiaochun, Yang, Chao, Yang, Jingqiang, Yang, Lixian, Yu, Jingjing, Zhang, Yingzhou, Zhang, Zhisheng, Zhou, Xinping
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Pyrotinib-based therapy for patients with HER2-positive breast cancer: A multicenter, real-world study
Wang, Haoqi, Liu, Yueping, Yang, Hua, Wang, Shuaibing, Cui, Guozhong, Ma, Jie, Liu, Yunjiang, Li, Xianqiao, Luo, Ruizhen, Zhang, Wei, Geng, Cuizhi
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article